Drug intelligence / Profile preview

BK1901

Development stage: Unknown
Lead developer: Research Foundation for Microbial Diseases of Osaka University
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**BK1901** is an investigational DTPa-IPV combination booster vaccine developed by The Research Foundation for Microbial Diseases of Osaka University for booster immunization against pertussis, diphtheria, tetanus, and poliomyelitis. It is designed to induce protective active immunity against *Bordetella pertussis*, *Corynebacterium diphtheriae*, *Clostridium tetani*, and poliovirus. The BIKEN pipeline lists BK1901 in Phase 2, and the Japanese clinical-trial registry identifies a Phase 2 booster study in healthy Japanese children. ([biken.or.jp](https://www.biken.or.jp/research/))

Other names: DPT-IPV booster vaccineDiphtheria-Pertussis-Tetanus-Inactivated Poliovirus booster vaccineDPT-sIPV booster vaccine

Beyond the preview

Go deeper on BK1901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BK1901.

Explore the full profile